AVXL
Anavex Life Sciences
stockNASDAQ
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson's disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.54 | 2026-10-08 | -3.90% | -2.185 |
| 1M | 2.44 | 2026-09-15 | -39.34% | 0.070 |
| 3M | 2.50 | 2026-07-15 | -40.80% | 2.149 |
| 6M | 3.24 | 2026-04-15 | -54.32% | 1.886 |
| 1Y | 9.03 | 2025-10-15 | -83.61% | 1.750 |
| 2Y | 5.39 | 2024-10-15 | -72.54% | — |
| 5Y | 17.52 | 2021-10-15 | -91.55% | 1.706 |
Anavex Life Sciences (NASDAQ:AVXL) stock price today is $1.48, and today's volume is 985,037. AVXL is down 0.671% today. The 30 day average volume is 1.05M. AVXL market cap is $137.19M with 92.70M shares outstanding.